Nasdaq · Healthcare

LEXICON PHARMACEUTICALS, INC. (LXRX)

As-reported financials and recent SEC filings for LEXICON PHARMACEUTICALS, INC., latest fiscal period FY2025. Every figure is pulled straight from the company’s EDGAR filings — no estimates.

Snapshot

Revenue

$49.8M

Net income

$-50.3M

Net margin

-101.1%

Diluted EPS

$-0.14

ROE

-46.8%

P/E (TTM)

—

Market cap

—

Debt / equity

0.5×

Income statement (as reported)

Line	FY2025	FY2024	FY2023	FY2019	FY2019
Revenue	$49.8M	$31.1M	$1.2M	$139,000	$298,000
Gross profit	—	—	—	—	—
Operating income	$-48.9M	$-197.1M	$-171.8M	$-100.8M	$-87.1M
Net income	$-50.3M	$-200.4M	$-177.1M	$-101.9M	$-87.8M
Diluted EPS	$-0.14	$-0.63	$-0.80	$-0.62	$-0.60

Source: company XBRL financial statements on SEC EDGAR.

Recent SEC filings

42026-06-04

42026-06-04

42026-06-04

42026-06-04

42026-06-04

42026-06-04

42026-06-04

42026-05-08

Largest Healthcare peers

UNH

UNITEDHEALTH GROUP INC

All Healthcare companies →

Go deeper on LXRX

Search LEXICON PHARMACEUTICALS, INC.’s filings with cited answers, compare it against peers, build an operating model, and track it in your portfolio — all in one place.

Start free

Or check your whole portfolio free — no account needed.

Data sourced from SEC EDGAR (public domain). Figures are as-reported and may be unaudited or restated; verify against the source filing before relying on them. Informational only — not investment advice.